Adverse events associated with mirabegron 50mg versus placebo: A systematic review and meta-analysis.

Hou, J; Xu, F; Du, H; Li, N

Hou, J; Xu, F; Du, H; Li, N.

Afiliação

Hou J; Department of Urology, Fourth Affiliated Hospital, China Medical University, 4 Chong Shan East Road, Shenyang, Liaoning, China.
Xu F; Department of Urology, Fourth Affiliated Hospital, China Medical University, 4 Chong Shan East Road, Shenyang, Liaoning, China.
Du H; Department of Urology, Fourth Affiliated Hospital, China Medical University, 4 Chong Shan East Road, Shenyang, Liaoning, China.
Li N; Department of Urology, Fourth Affiliated Hospital, China Medical University, 4 Chong Shan East Road, Shenyang, Liaoning, China. Electronic address: air-nick@hotmail.com.

Prog Urol ; 31(11): 627-633, 2021 Sep.

Article em En | MEDLINE | ID: mdl-34312078

Assuntos

Bexiga Urinária Hiperativa; Agentes Urológicos; Acetanilidas/efeitos adversos; Humanos; Tiazóis/efeitos adversos; Resultado do Tratamento; Bexiga Urinária Hiperativa/tratamento farmacológico

Palavras-chave

Adverse events; Essai randomisé; Meta-analysis; Mirabegron; Méta-analyse; Nasopharyngitis; Safety; Syndrome d'hyperactivité vésicale

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bexiga Urinária Hiperativa / Agentes Urológicos Tipo de estudo: Clinical_trials / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google